Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.

BMC Cancer · 2009 · PMC2771045 · PMID 19840379

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp < 0.0001actually significant

Defining tumoral growth as the ratio between the final and initial tumor volumes, the increase during the treatment duration was on average 2.0 ± 0.7 (range: 1.4 - 3.2) and was highly significant (p < 0.0001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.